Abstract: OBJECTIVE To explore the efficacy and safety of treatment regimens for patients with advanced non-small cell lung cancer(NSCLC) with v-Raf murine sarcoma viral oncogene homolog B1(BRAF) V600E positive mutation, and to provide reference for pharmacological monitoring of these patients. METHODS Two cases of advanced NSCLC patients with BRAF V600E positive mutation admitted to Tianjin Medical University Cancer Institute & Hospital from 2018 to 2019 were analyzed, and the treatment regimens were evaluated in the context of the patients’ disease changes and treatment guidelines, with drug use, medication education and adverse reaction monitoring as the starting points. To implement pharmaceutical care for advanced NSCLC patients with BRAF-positive mutations, and assist clinicians to deal with related adverse reactions in a timely manner. RESULTS Two patients with advanced NSCLC with BRAF V600E mutation showed certain antitumor activity after receiving BRAF and mitogen-activated extracellular signal-regulated kinase inhibitor combination therapy, and the adverse reactions were within the control range. CONCLUSION Clinical pharmacists can promote rational clinical use of drugs through pharmacological monitoring, aiming to protect the safety and efficacy of patients’ medications.